CIK 0001827635 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Veradermics, Inc
Sign in to watch- Ticker
- MANE
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 843304423
- Phone
- 228.372.3376
- Business address
- 470 JAMES STREET, NEW HAVEN, CT, 06513
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $242,788,217
- in 5 filings, $12.0M under 10b5-1 plans
Net −$242,788,217. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- MONTANOVA CAPITAL, LLC −$80.4M Director sold 62% of stake
- ENRIGHT PATRICK G −$75.2M Director sold 22% of stake
- Longitude Capital Partners V, LLC −$75.2M 10% owner sold 22% of stake
- Waldman Reid Alexander −$7.3M Chief Executive Officer sold 28% of stake
- Durso Timothy August −$4.7M Chief Technical Officer sold 36% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-17 | Waldman Reid Alexander Chief Executive Officer | Sale 10b5-1 | −11,527 | $106.72 | $1.2M | 226,797 |
| 2026-08-17 | Waldman Reid Alexander Chief Executive Officer | Sale 10b5-1 | −25,234 | $107.53 | $2.7M | 201,563 |
| 2026-08-17 | Waldman Reid Alexander Chief Executive Officer | Sale 10b5-1 | −27,490 | $108.45 | $3.0M | 174,073 |
| 2026-08-17 | Waldman Reid Alexander Chief Executive Officer | Sale 10b5-1 | −3,000 | $109.38 | $328K | 171,073 |
| 2026-08-17 | Waldman Reid Alexander Chief Executive Officer | Sale 10b5-1 | −249 | $111.28 | $28K | 170,824 |
| 2026-08-17 | Waldman Reid Alexander Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,452 | 0 | ||
| 2026-08-12 | CHILDS JOHN W Director | Sale | −15,000 | $106.14 | $1.6M | 279,117 |
| 2026-08-12 | CHILDS JOHN W Director | Sale | −80,000 | $107.23 | $8.6M | 199,117 |
| 2026-08-12 | CHILDS JOHN W Director | Sale | −5,000 | $108.24 | $541K | 194,117 |
| 2026-05-01 | SUVRETTA CAPITAL MANAGEMENT, LLC Director | Grant or award · Pre-Funded Warrants | +149,000 | $100.00 | $14.9M | 149,000 |
| 2026-05-01 | SUVRETTA CAPITAL MANAGEMENT, LLC Director | Grant or award · Pre-Funded Warrants | +151,000 | $100.00 | $15.1M | 151,000 |
| 2026-02-06 | SUVRETTA CAPITAL MANAGEMENT, LLC Director | Purchase | +11,183 | $35.97 | $402K | 501,115 |
| 2026-02-06 | SUVRETTA CAPITAL MANAGEMENT, LLC Director | Purchase | +19,338 | $36.55 | $707K | 520,453 |
| 2026-02-05 | CHILDS JOHN W Director | Purchase | +294,117 | $17.00 | $5.0M | 294,117 |
| 2026-02-05 | SUVRETTA CAPITAL MANAGEMENT, LLC Director | Purchase | +3,832 | $36.07 | $138K | 397,564 |
| 2026-02-05 | SUVRETTA CAPITAL MANAGEMENT, LLC Director | Purchase | +19,199 | $36.93 | $709K | 416,763 |
| 2026-02-05 | SUVRETTA CAPITAL MANAGEMENT, LLC Director | Purchase | +38,771 | $37.63 | $1.5M | 455,534 |
| 2026-02-05 | SUVRETTA CAPITAL MANAGEMENT, LLC Director | Purchase | +17,835 | $38.67 | $690K | 473,369 |
| 2026-02-05 | SUVRETTA CAPITAL MANAGEMENT, LLC Director | Purchase | +16,563 | $39.80 | $659K | 489,932 |
| 2026-02-05 | Grant-Kels Jane M. Director | Conversion | +2,455 | 2,455 |
Page 2 of 6 · 107 trades